Annual Total Liabilities
$206.00 K
+$19.00 K+10.16%
31 December 2023
Summary:
XTL Biopharmaceuticals annual total liabilities is currently $206.00 thousand, with the most recent change of +$19.00 thousand (+10.16%) on 31 December 2023. During the last 3 years, it has fallen by -$2.69 million (-92.87%). XTLB annual total liabilities is now -96.58% below its all-time high of $6.02 million, reached on 31 December 2004.XTLB Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Liabilities
$223.00 K
+$17.00 K+8.25%
31 March 2024
Summary:
XTL Biopharmaceuticals quarterly total liabilities is currently $223.00 thousand, with the most recent change of +$17.00 thousand (+8.25%) on 31 March 2024. Over the past year, it has increased by +$61.00 thousand (+37.65%). XTLB quarterly total liabilities is now -96.64% below its all-time high of $6.64 million, reached on 30 June 2008.XTLB Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
XTLB Total Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +10.2% | +37.6% |
| 3 y3 years | -92.9% | -94.1% |
| 5 y5 years | -84.2% | +11.5% |
XTLB Total Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -92.9% | +10.2% | -94.1% | +45.8% |
| 5 y | 5 years | -92.9% | +10.2% | -94.1% | +45.8% |
| alltime | all time | -96.6% | +10.2% | -96.6% | +45.8% |
XTL Biopharmaceuticals Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2024 | - | $223.00 K(+8.3%) |
| Dec 2023 | $206.00 K(+10.2%) | $206.00 K(+27.2%) |
| Sept 2023 | - | $162.00 K(-0.6%) |
| June 2023 | - | $163.00 K(-32.4%) |
| Mar 2023 | - | $241.00 K(+28.9%) |
| Dec 2022 | $187.00 K(-85.4%) | $187.00 K(+22.2%) |
| Sept 2022 | - | $153.00 K(-21.1%) |
| June 2022 | - | $194.00 K(-75.0%) |
| Mar 2022 | - | $777.00 K(-39.5%) |
| Dec 2021 | $1.28 M(-55.6%) | $1.28 M(-66.0%) |
| Sept 2021 | - | $3.78 M(+2.9%) |
| June 2021 | - | $3.67 M(+24.7%) |
| Mar 2021 | - | $2.94 M(+1.8%) |
| Dec 2020 | $2.89 M(+314.8%) | $2.89 M(+1488.5%) |
| Sept 2020 | - | $182.00 K(-6.2%) |
| June 2020 | - | $194.00 K(-20.5%) |
| Mar 2020 | - | $244.00 K(-65.0%) |
| Dec 2019 | $697.00 K(-46.5%) | $697.00 K(+248.5%) |
| Sept 2019 | - | $200.00 K(-1.5%) |
| June 2019 | - | $203.00 K(-14.0%) |
| Mar 2019 | - | $236.00 K(-81.9%) |
| Dec 2018 | $1.30 M(-56.1%) | $1.30 M(+560.9%) |
| Sept 2018 | - | $197.00 K(-0.5%) |
| June 2018 | - | $198.00 K(-14.7%) |
| Mar 2018 | - | $232.00 K(-92.2%) |
| Dec 2017 | $2.97 M(+799.1%) | $2.97 M(-7.4%) |
| Sept 2017 | - | $3.21 M(-36.9%) |
| June 2017 | - | $5.08 M(+18.4%) |
| Mar 2017 | - | $4.29 M(+1201.2%) |
| Dec 2016 | $330.00 K(-24.3%) | $330.00 K(+42.9%) |
| Sept 2016 | - | $231.00 K(-10.5%) |
| June 2016 | - | $258.00 K(-30.6%) |
| Mar 2016 | - | $372.00 K(-14.7%) |
| Dec 2015 | $436.00 K | $436.00 K(+66.4%) |
| Sept 2015 | - | $262.00 K(+13.4%) |
| June 2015 | - | $231.00 K(-95.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2015 | - | $5.01 M(+419.5%) |
| Dec 2014 | $965.00 K(-21.5%) | $965.00 K(-20.3%) |
| Sept 2014 | - | $1.21 M(-11.9%) |
| June 2014 | - | $1.38 M(+4.6%) |
| Mar 2014 | - | $1.31 M(+6.9%) |
| Dec 2013 | $1.23 M(-26.0%) | $1.23 M(-5.5%) |
| Sept 2013 | - | $1.30 M(-5.8%) |
| June 2013 | - | $1.38 M(-13.3%) |
| Mar 2013 | - | $1.59 M(-4.1%) |
| Dec 2012 | $1.66 M(-59.2%) | $1.66 M(+125.2%) |
| Sept 2012 | - | $738.00 K(-11.3%) |
| June 2012 | - | $832.00 K(-16.9%) |
| Mar 2012 | - | $1.00 M(-75.4%) |
| Dec 2011 | $4.07 M(+7.3%) | $4.07 M(+533.4%) |
| Sept 2011 | - | $643.00 K(-7.9%) |
| June 2011 | - | $698.00 K(-15.4%) |
| Mar 2011 | - | $825.00 K(-78.3%) |
| Dec 2010 | $3.80 M(+431.0%) | $3.80 M(+328.1%) |
| Sept 2010 | - | $887.00 K(+0.6%) |
| June 2010 | - | $882.00 K(+20.3%) |
| Mar 2010 | - | $733.00 K(+2.5%) |
| Dec 2009 | $715.00 K(-79.0%) | $715.00 K(+13.0%) |
| Sept 2009 | - | $633.00 K(-81.4%) |
| Dec 2008 | $3.40 M(-38.8%) | $3.40 M(-48.8%) |
| June 2008 | - | $6.64 M(+19.4%) |
| Dec 2007 | $5.56 M(+34.4%) | $5.56 M(+24.2%) |
| June 2007 | - | $4.48 M(+8.2%) |
| Dec 2006 | $4.14 M(+6.2%) | $4.14 M(-0.1%) |
| June 2006 | - | $4.15 M(+6.3%) |
| Dec 2005 | $3.90 M(-35.3%) | $3.90 M(-19.3%) |
| June 2005 | - | $4.83 M(-19.8%) |
| Dec 2004 | $6.02 M(+41.9%) | $6.02 M(+4.3%) |
| June 2004 | - | $5.77 M |
| Dec 2003 | $4.25 M(+18.1%) | - |
| Dec 2002 | $3.59 M(+14.0%) | - |
| Dec 2001 | $3.15 M | - |
FAQ
- What is XTL Biopharmaceuticals annual total liabilities?
- What is the all time high annual total liabilities for XTL Biopharmaceuticals?
- What is XTL Biopharmaceuticals annual total liabilities year-on-year change?
- What is XTL Biopharmaceuticals quarterly total liabilities?
- What is the all time high quarterly total liabilities for XTL Biopharmaceuticals?
- What is XTL Biopharmaceuticals quarterly total liabilities year-on-year change?
What is XTL Biopharmaceuticals annual total liabilities?
The current annual total liabilities of XTLB is $206.00 K
What is the all time high annual total liabilities for XTL Biopharmaceuticals?
XTL Biopharmaceuticals all-time high annual total liabilities is $6.02 M
What is XTL Biopharmaceuticals annual total liabilities year-on-year change?
Over the past year, XTLB annual total liabilities has changed by +$19.00 K (+10.16%)
What is XTL Biopharmaceuticals quarterly total liabilities?
The current quarterly total liabilities of XTLB is $223.00 K
What is the all time high quarterly total liabilities for XTL Biopharmaceuticals?
XTL Biopharmaceuticals all-time high quarterly total liabilities is $6.64 M
What is XTL Biopharmaceuticals quarterly total liabilities year-on-year change?
Over the past year, XTLB quarterly total liabilities has changed by +$61.00 K (+37.65%)